| European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia JL Steegmann, M Baccarani, M Breccia, LF Casado, V García-Gutiérrez, ... Leukemia 30 (8), 1648-1671, 2016 | 502 | 2016 |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ... Journal of Clinical Oncology 36 (3), 231-237, 2018 | 494 | 2018 |
| Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study A Hochhaus, T Masszi, FJ Giles, JP Radich, DM Ross, ... Leukemia 31 (7), 1525-1531, 2017 | 310 | 2017 |
| Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients A Tefferi, EA Wassie, P Guglielmelli, N Gangat, AA Belachew, TL Lasho, ... American journal of hematology 89 (8), E121-E124, 2014 | 259 | 2014 |
| A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs D Rea, MJ Mauro, C Boquimpani, Y Minami, E Lomaia, S Voloshin, ... Blood, The Journal of the American Society of Hematology 138 (21), 2031-2041, 2021 | 215 | 2021 |
| Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation A Alvarez-Larrán, A Pereira, P Guglielmelli, JC Hernández-Boluda, ... haematologica 101 (8), 926, 2016 | 166 | 2016 |
| Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study DM Ross, T Masszi, MT Gómez Casares, A Hellmann, J Stentoft, ... Journal of cancer research and clinical oncology 144, 945-954, 2018 | 154 | 2018 |
| Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety V García-Gutiérrez, JC Hernández-Boluda Frontiers in oncology 9, 603, 2019 | 136 | 2019 |
| Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study NP Shah, V García-Gutiérrez, A Jiménez-Velasco, S Larson, S Saussele, ... Leukemia & lymphoma 61 (3), 650-659, 2020 | 130 | 2020 |
| High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib T Barbui, AM Vannucchi, A Alvarez-Larran, A Iurlo, A Masciulli, ... Leukemia 35 (2), 485-493, 2021 | 90 | 2021 |
| Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors A Hochhaus, M Breccia, G Saglio, V García-Gutiérrez, D Réa, J Janssen, ... Leukemia 34 (6), 1495-1502, 2020 | 86 | 2020 |
| Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study V Escamilla Gómez, V García-Gutiérrez, L López Corral, ... Bone marrow transplantation 55 (3), 641-648, 2020 | 85 | 2020 |
| Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera A Alvarez‐Larrán, A Kerguelen, JC Hernández‐Boluda, M Pérez‐Encinas, ... British Journal of Haematology 172 (5), 786-793, 2016 | 83 | 2016 |
| Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea A Alvarez-Larrán, M Pérez-Encinas, F Ferrer-Marín, ... haematologica 102 (1), 103, 2017 | 68 | 2017 |
| Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis AT Gerds, MR Savona, BL Scott, M Talpaz, M Egyed, CN Harrison, ... Blood Advances 4 (22), 5825-5835, 2020 | 67 | 2020 |
| Estrategias para el desarrollo de los temas transversales del currículum J Palos, D Casas, G Doménech, C García, C Jiménez, E Quesada, ... Universitat de Barcelona. Institut de Ciències de l'Educació; Editorial Horsori, 2000 | 67 | 2000 |
| Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial TH Brümmendorf, JE Cortes, D Milojkovic, C Gambacorti-Passerini, ... Leukemia 36 (7), 1825-1833, 2022 | 66 | 2022 |
| Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia JC Hernández-Boluda, E Arellano-Rodrigo, F Cervantes, ... Annals of hematology 94, 911-918, 2015 | 60 | 2015 |
| SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish hematopoietic stem … JL Piñana, L López‐Corral, R Martino, J Montoro, L Vazquez, A Pérez, ... American Journal of Hematology 97 (1), 30-42, 2022 | 58 | 2022 |
| Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective … G Orti, J Sanz, A Bermudez, D Caballero, C Martinez, J Sierra, JRC Marin, ... Biology of Blood and Marrow Transplantation 22 (3), 584-588, 2016 | 58 | 2016 |
